Skip to main content

Table 2 Baseline characteristics of the 207 kidney transplants included in the study a

From: Effect of donor non-muscle myosin heavy chain (MYH9) gene polymorphisms on clinically relevant kidney allograft dysfunction

A. Recipients
 Women, n (%) 83 (40.1)    
 Age at transplantation (years) 48.1 ± 13.8 (19.0–77.0)   
 Last PRA > 20%, n (%) 19 (8.3)    
 Retransplants, n (%) 41 (19.8)    
 HLA mismatch, n (%)
  0–2 65 (31.7)    
  3–4 115 (56.1)    
  5–6 25 (12.2)    
 Delayed Graft Functionbc (DGF), n (%) 58 (34.0)    
 Primary kidney disease, n (%)
  diabetes 21 (10.1)    
  ADPKD 34 (16.4)    
  GN 83 (40.1)    
  hypertensive nephropathy 12 (5.8)    
  other or unknown 57 (27.5)    
 Dialysis before Tx (years) 4.6 ± 5.1 (0–31.3)    
 Preemptive Tx, n (%) 3 (1.4)    
 Induction with ATG or aIL2, n (%) 64 (31.5)    
 Cyclosporine A, n (%) 53 (25.6)    
 Tacrolimus, n (%) 154 (74.4)    
 Mycophenolic acid preparation, n (%) 205 (99.0)    
 Acute rejection within 1 yr, n (%) 35 (16.9)    
B. Transplanted kidneys
 Donor sex (woman), n (%) 83 (40.3)    
 Donor age (years) 44.3 ± 13.9 (13.0–65.0)   
 Donor cause of deathc, n (%)
  stroke 110 (60.8)    
  trauma 63 (34.8)    
  other 8 (4.4)    
 Preservation with pulsative perfusion, n(%) 126 (61.2)    
 TITd (hours) 26.8 ± 8.1 (5.8–50.5)   
 Donor MYH9 SNP n (%) n (%) n (%) HWE p
 rs11089788 AA: 55 (26.6%) AC:105(50.7%) CC: 47(22.7%) 0.707
 rs136211 AA: 21 (10.1%) AG: 91 (44%) GG: 95(45.9%) 0.908
 rs2239784 CC: 187 (90.3%) CT: 20 (9.7%) TT: 0 (0%) 0.442
 rs3752462 CC: 112 (54.1%) CT: 79(38.2%) TT: 16 (7.7%) 0.580
 rs5756168 CC: 3 (1.4%) CT: 39(18.8%) TT: 165(79.7%) 0.691
 rs4821480 GG: 1(< 1%) GT: 27(13%) TT: 179(86.5%) 0.987
  1. a quantitative variables are expressed as mean ± SD (range);
  2. bDue to missing data, the number of cases does not always add up to 207
  3. cMissing data for 37 transplants
  4. d Missing data for 40 transplants